Introduction
============

Pain has been the most common problem encountered in the immediate postoperative period. Effective control of this pain has become essential as it helps in providing early mobilization, better recovery, and cost-effective hospital stay, especially in patients undergoing orthopedic surgeries. Acute pain if left untreated may lead to chronicity and become persistent which imposes a greater burden on the patient, as treatment modalities for chronic pain is limited and rarely effective.[@b1-jpr-10-2471] The existing medications used to relieve pain following orthopedic surgeries are nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, local anesthetics, gabapentinoids, antiepileptics, and steroids, but they are often accompanied by adverse effects.[@b2-jpr-10-2471] Hence, the need for further studies in this regard has become necessary.

Piroxicam, an oxicam-derived NSAID, inhibits prostaglandin-mediated pain and inflammation. The advantages of this group of drugs over the other analgesics are decreased sensitization of peripheral receptors, absence of addiction potential, and cognitive impairment. It is used for postoperative pain relief, musculoskeletal disorders, and arthritis.

Flupirtine, a nonopioid, non-NSAID drug, belongs to K~V~7 potassium channel openers, exerting its action by exhibiting antagonism on N-methyl-[d]{.smallcaps}-aspartate (NMDA) receptors of glutamate. In addition, it also exerts therapeutic action via GABA~A~ergic receptors.[@b3-jpr-10-2471],[@b4-jpr-10-2471] It has a unique analgesic and skeletal muscle relaxing property and hence used in the management of musculoskeletal ailments. It is devoid of adverse effects like gastritis, renal compensation, and respiratory depression and therefore found to be safe in most patients. Though earlier studies have shown that flupirtine produces analgesia,[@b4-jpr-10-2471],[@b5-jpr-10-2471] there is dearth of research related to its ability in yielding postoperative analgesia, and hence, the present study was carried out to assess the efficacy of flupirtine and piroxicam in postoperative pain using visual analog scale (VAS) score, the total amount of rescue analgesic required, and patient's satisfaction score and to evaluate safety profile of the above drugs using WHO causality scale.

Materials and methods
=====================

A randomized, open-label, parallel group, comparative study was conducted by the departments of pharmacology and orthopedics on patients undergoing lower limb surgery in a tertiary care hospital from January 2015 to July 2016. All patients of either gender aged between 18 and 50 years undergoing either elective or emergency lower limb surgery with or without the requirement of implants and belonging to American Society of Anaesthesiologists (ASA) grade I and II were recruited. Patients with hepatic and renal impairment, hemorrhagic disorders, bronchial asthma, addictive disorders such as smoking, alcoholism, any other drugs of abuse, history of peptic ulcer, and gastrointestinal bleeding, pregnant and lactating women, and those with known hypersensitivity to the study medications were excluded from the study.

A pro forma containing detailed information of each patient was designed according to the study protocol. Ethical clearance was obtained from the institutional ethics committee affiliated to Sri Devaraj Urs Medical College. Patients undergoing elective or emergency lower limb surgery were recruited. After obtaining written informed consent, the patients were randomized using block randomization method. A block size of four was used and with the help of computer, random numbers for all the patients were generated, and the patients were assigned to two groups of 38 patients each. Baseline assessments included demographic details, clinical history, and examination. The patients were acquainted to the pain scores prior to start of the treatment with the study drugs and were requested to report any adverse events that they experienced during their stay in the hospital. Following surgery, both the groups received single dose of tramadol 100 mg injection intravenously in the recovery room. Six hours after surgery, patients in group F received flupirtine 100 mg twice daily and group P received piroxicam 20 mg twice daily orally for 5 days.

Intensity of pain was measured using VAS score from 0 to 10 (0 is no pain and 10 is worst pain). VAS score was measured at baseline (before the study medication was administered) and at 2, 4, 8, 12, 24, 48, 72, 96, and 120 hours. Total pain relief (TOTPAR~24~) score for first 24 hours was also assessed. The objective evaluation of pain was done using Behavioral Pain Assessment Scale (BPAS) (scored 0--10) and functional activity score (FAS) (scored A--C) at 12, 24, 48, 72, 96, and 120 hours.

Patient's pulse rate, blood pressure, and respiratory rate were monitored immediately after recovery from anesthesia and at 2, 4, 8, 12, 24, 48, 72, 96, and 120 hours postoperatively. Patients were administered tramadol 100 mg injection intravenously as rescue medication if VAS score was \>3 during the postoperative period. Patients' satisfaction with respect to pain relief was assessed using patient satisfaction score (PSS) at the end of 24 hours postoperatively. Adverse effects for both the drugs were monitored and causality assessed using WHO scale.

Statistical methods
-------------------

To detect a mean difference of 0.7 in VAS with an effect size of 0.75, an alpha error of 5%, and a power of 80% with a dropout rate of 10%, the required sample size was calculated to be 38 patients per group.[@b5-jpr-10-2471] The demographic data were assessed using descriptive statistics. The VAS and BPAS scores were assessed by repeated measures ANOVA followed by Bonferroni post hoc test within the group and unpaired *t*-test between the groups. TOTPAR~24~ and FAS were analyzed using descriptive statistics. PSS and need for rescue analgesia were analyzed using Mann--Whitney *U* test and chi-squared test, respectively. Adverse effects were analyzed using Fischer's exact test. *p*-value \<0.05 was considered to be statistically significant.

Results
=======

A total of 76 patients undergoing lower limb surgeries were recruited in this study. They were randomized using computer-generated, block randomization method to either group F or P. The surgeries were performed under spinal anesthesia using 3mL of 0.5% bupivacaine. All the patients received intravenous fentanyl 25μg intraoperatively, and following surgery, they received single dose of tramadol 100 mg injection intravenously in the recovery room. Patients in group F received flupirtine 100 mg capsule and those in group P received piroxicam 20 mg tablet. Both the drugs were administered orally 6 hours after surgery and twice daily for the next 5 days. Seventy one patients completed the study. [Figure 1](#f1-jpr-10-2471){ref-type="fig"} represents patient recruitment and follow-up.

The baseline characteristics were comparable in both the groups ([Table 1](#t1-jpr-10-2471){ref-type="table"}). Among the 76 patients recruited, 65 were male and 11 female with an overall literacy rate of 59.21%. The type of surgeries are shown in [Table 1](#t1-jpr-10-2471){ref-type="table"}, those requiring the placement of orthopedic implants contributed to 46.1% of the total patients, and the distribution of type of surgeries between the groups was comparable (*p*=0.054).

[Table 2](#t2-jpr-10-2471){ref-type="table"} shows the reduction in VAS score over time in patients of both the groups. The reduction in intensity of pain in Groups F and P was statistically significant at 48 hours and onwards compared to baseline. Piroxicam significantly reduced pain compared to flupirtine at 8, 12, and 120 hours. The pain experienced by a patient was also graded as mild, moderate, and severe. Moderate pain was observed up to 72 hours by 55.9% patients in group F and 48.6% in group P, thereafter the intensity reduced to mild pain in both the groups.

The area under the curve for postoperative pain in patients receiving two different medications ([Figure 2](#f2-jpr-10-2471){ref-type="fig"}) was calculated by trapezoid rule which showed that the pain intensity expressed as TOTPAR~24~ for the first 24 hours was lesser with piroxicam (116.38) than flupirtine (127.8), and a similar observation was noted there after upto 120 hours (piroxicam 332.64 and flupirtine 360).

A decrease in mean BPAS scores was observed in both the groups ([Figure 3](#f3-jpr-10-2471){ref-type="fig"}) and was statistically significant within the group at all-time intervals of assessment after 24 hours postoperatively, compared to baseline. At baseline, only 23/71 of the patients could be assessed for FAS, of which 65.2% and 34.8% had mild to severe limitation of activity in groups F and P, respectively ([Table 3](#t3-jpr-10-2471){ref-type="table"}). In group F, 6% of patients and, in group P, 27% had no limitation of activity at 72 hours, and this improvement was observed in 59% and 54% of patients at 120 hours.

In 55.9% of patients in group F and 59.5% in Group P, the satisfaction score was "Good" ([Figure 4](#f4-jpr-10-2471){ref-type="fig"}), and it was comparable (*p*=0.698). The rescue analgesic tramadol was required by 18 and 22 patients in groups F and P, respectively, and it was insignificant between the groups (*p*=0.580). Most patients (62.5%) in both the groups required one to two doses of the medication over the study period of 5 days, and there was no significant difference in the number of doses between the groups (*p*=0.365).

The most common adverse effect was dyspepsia which was observed in one patient receiving flupirtine and in three patients receiving piroxicam which was not statistically significant (*p*=0.40). The effects of the study drugs on pulse, blood pressure, and respiratory rate were assessed at different time intervals. There was no significant difference in these vital parameters within or between the groups.

Discussion
==========

Pain management in postsurgical patients has been a major concern over the last few decades.[@b6-jpr-10-2471] It is one of the important aspects to be considered because it is closely related to good clinical outcome. Orthopedic procedures can cause severe intraoperative and postoperative pain which is indicative of tissue damage and is usually a major clinical problem occurring in 62%--65% of patients.[@b7-jpr-10-2471],[@b8-jpr-10-2471] Thus, effective pain management is needed for the recovery of range of movements, muscle strength for ambulation, rapid rehabilitation, shorter hospital stay, and to improve the quality of life of patients.[@b9-jpr-10-2471]

In our study, majority were male patients with a mean age of 35±10 years. Only patients undergoing lower limb surgeries were recruited as the sensitivity of pain differs among different bones. The distribution of type of surgeries between the groups was comparable and implant placements were predominant. The mean duration of surgery was similar in patients receiving either medication. At baseline, the mean VAS score was comparable between the two groups. The reduction in pain was significant at all points of time following 48 hours treatment compared to baseline in both the groups. This observation partly correlates with the findings of another study,[@b10-jpr-10-2471] indicating that though both the study drugs have a slight delay in onset, they have a longer duration of analgesia. Flupirtine used as preemptive analgesic in laparoscopic cholecystectomy surgery had provided adequate pain relief postoperatively in a study conducted by Yadav et al[@b11-jpr-10-2471] and in postabdominal hysterectomy study conducted by Thapa et al.[@b12-jpr-10-2471] These studies indicate that preemptive use of flupirtine could provide immediate postoperative pain relief; hence, administering this drug preemptively followed by postoperative dosing may be a better method for postoperative analgesia in orthopedic surgeries.

In patients who received piroxicam, reduction in pain was significant at 8, 12, and 120 hours postoperatively compared to flupirtine. This suggests that patients receiving piroxicam had better analgesic effect compared to flupirtine. The TOTPAR~24~ which is a measure of continuous pain relief also showed that piroxicam was better in relieving pain. However, a study conducted by Yadav et al proved flupirtine to provide better analgesia than diclofenac[@b13-jpr-10-2471] and that by Naser et al[@b5-jpr-10-2471] showed equal efficacy of flupirtine and ibuprofen in terms of analgesia when used in gynecological surgeries. Similar studies by Attri et al and Ahuja et al, which compared flupirtine with other NSAIDs, also revealed no significant difference between the medications in reducing postoperative pain.[@b5-jpr-10-2471],[@b10-jpr-10-2471],[@b14-jpr-10-2471] These studies were conducted on patients undergoing gynecological and other abdominal surgeries unlike the current study which was carried out in limb surgeries. The extensiveness and increased sensitivity of osteoid tissues tend to result in severe postoperative pain following surgeries involving the bone. Thereby, the current study that assessed the efficacy of drugs on pain showed piroxicam to provide better analgesia than flupirtine.

The objective BPAS showed a reduction with both the medications, which reflects pain relief, but another study has shown reduction in VAS score at an earlier point of time compared to BPAS score.[@b15-jpr-10-2471] Improvement in the FAS reflects improvement in the range of movements in the operated limb. Majority of patients who had moderate to severe limitation of activity at baseline improved over the first 96 hours, and this was earlier in patients receiving piroxicam.

PSS at the end of 24 hours was good in 56% and 60% in flupirtine and piroxicam groups. There was no significant difference in their satisfaction score, which indicates that patients were contended with the medication they received. However, a study comparing similar drugs showed flupirtine to have superior satisfaction score.[@b14-jpr-10-2471] In our study, the requirement of rescue analgesic was similar with both the medications, which was similar to another study.[@b14-jpr-10-2471] In this study, the adverse effects were dyspepsia and dizziness. Dyspepsia was the only adverse effect in piroxicam group and is due to inhibition of protective effect of prostaglandin on gastric mucosa. Dizziness that occurred in a patient who received flupirtine could be attributed to the hypotension, which is a common side effect with flupirtine due to its effect on the K~v~7 channels in vascular smooth muscle.[@b4-jpr-10-2471] The study drugs showed no effect on the vital parameters such as pulse rate, blood pressure, and respiratory rate.

The findings of our study imply that pain relief was similar with both the drugs but the onset was earlier with piroxicam. In individuals with history or risk of dyspepsia, flupirtine may be preferred.

Conclusion
==========

Flupirtine and piroxicam reduced pain effectively in patients following lower limb surgery but onset of pain relief was earlier with piroxicam.
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![Flowchart representing recruitment of patients.](jpr-10-2471Fig1){#f1-jpr-10-2471}

![Areas under the curve for flupirtine and piroxicam.\
**Notes:** ^@^*p*=0.006, ^♣^*p*=0.0001, comparison with baseline in flupirtine group. ^β^*p*=0.0001, comparison with baseline in piroxicam group. Intergroup comparison; \**p*=0.028 at 8 hours, ^\#^*p*=0.032 at 12 hours, ^\$^*p*=0.021 at 120 hours.\
**Abbreviations:** BL, baseline; VAS, visual analog scale.](jpr-10-2471Fig2){#f2-jpr-10-2471}

![Comparison of mean BPAS scores within the groups.\
**Notes:** ^♣^*p*=0.0001, comparison with baseline in flupirtine group. ^\$^*p*=0.0001, comparsion with baseline in piroxicam group.\
**Abbreviations:** BL, baseline; BPAS, behavioral pain assessment scale.](jpr-10-2471Fig3){#f3-jpr-10-2471}

![Patient satisfaction score in both the groups at the end of 24 hours.](jpr-10-2471Fig4){#f4-jpr-10-2471}

###### 

Baseline characteristics of all patients in both the groups

  Variables                                Flupirtine group (n=38)   Piroxicam group (n=38)   *p*-value
  ---------------------------------------- ------------------------- ------------------------ -----------
  Male/female                              32/6                      33/5                     0.744
  Age, mean ± SD (years)                   35.08±10.42               35.08±10.22              1.000
  Duration of surgery, mean ± SD (hours)   1.70±0.85                 1.48±0.86                0.283
  **Type of surgery**                                                                         0.054
  Implant placement surgeries              21                        14                       
  Implant removal                          5                         14                       
  Others                                   12                        10                       

###### 

VAS score in patients of both the groups at various time points

  Time in hours postoperatively   Flupirtine group (n=34)   Piroxicam group (n=37)                               *p*-value                                                        
  ------------------------------- ------------------------- ---------------------------------------------------- ----------- ---------------------------------------------------- ---------------------------------------------------
  Baseline                        5.8±1.6                                                                        5.6±1.7                                                          0.681
  2                               5.4±1.2                   1.000                                                5.1±1.4     0.660                                                0.253
  4                               5.6±1.5                   1.000                                                5.3±1.6     1.000                                                0.390
  8                               5.8±1.3                   1.000                                                5.1±1.5     1.000                                                0.028[\#](#tfn2-jpr-10-2471){ref-type="table-fn"}
  12                              5.3±1.1                   1.000                                                4.5±1.6     0.060                                                0.032[\#](#tfn2-jpr-10-2471){ref-type="table-fn"}
  24                              4.8±1.3                   0.171                                                4.7±1.4     0.058                                                0.713
  48                              4.4±1.1                   0.006[\*](#tfn1-jpr-10-2471){ref-type="table-fn"}    4.1±1.5     0.0001[\*](#tfn1-jpr-10-2471){ref-type="table-fn"}   0.354
  72                              3.8±1.2                   0.0001[\*](#tfn1-jpr-10-2471){ref-type="table-fn"}   3.6±1.3     0.0001[\*](#tfn1-jpr-10-2471){ref-type="table-fn"}   0.502
  96                              3.1±1.1                   0.0001[\*](#tfn1-jpr-10-2471){ref-type="table-fn"}   2.8±1.3     0.0001[\*](#tfn1-jpr-10-2471){ref-type="table-fn"}   0.346
  120                             2.6±1.1                   0.0001[\*](#tfn1-jpr-10-2471){ref-type="table-fn"}   2.1±0.8     0.0001[\*](#tfn1-jpr-10-2471){ref-type="table-fn"}   0.021[\#](#tfn2-jpr-10-2471){ref-type="table-fn"}

**Notes:**

Comparison with baseline;

intergroup comparison.

**Abbreviation:** VAS, visual analog scale.

###### 

Comparison of functional activity scores between two groups

  Time interval (hours)   Group        A (%)       B (%)       C (%)       NA (%)
  ----------------------- ------------ ----------- ----------- ----------- -----------
  Baseline                Flupirtine   0           5 (14.7)    10 (29.4)   19 (55.9)
  Piroxicam               0            5 (13.5)    3 (8.1)     29 (78.4)   
  12                      Flupirtine   0           16 (47.1)   18 (52.9)   0
  Piroxicam               1 (2.7)      19 (51.4)   17 (45.9)   0           
  24                      Flupirtine   0           24 (70.6)   10 (29.4)   0
  Piroxicam               3 (8.1)      23 (62.2)   11 (29.7)   0           
  48                      Flupirtine   0           32 (94.1)   2 (5.9)     0
  Piroxicam               5 (13.5)     28 (75.7)   4 (10.8)    0           
  72                      Flupirtine   2(5.9)      31 (91.2)   1 (2.9)     0
  Piroxicam               10 (27.0)    27 (73.0)   0           0           
  96                      Flupirtine   11 (32.4)   22 (64.7)   1 (2.9)     0
  Piroxicam               16 (43.2)    21 (56.8)   0           0           
  120                     Flupirtine   20 (58.8)   13 (38.2)   1 (2.9)     0
  Piroxicam               20 (54.1)    17 (45.9)   0           0           

**Notes:** A: no limitation (perform task without pain). B: mild limitation (perform task with minimal pain). C: severe limitation (unable to perform the task). NA: could not assess.
